EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
SMDC is a participating authority under Pharmaceutical Inspection Cooperation Scheme (PIC/S)
The new shadow roll-on delivers strong on-shelf presence with its modern rounded-base design
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Subscribe To Our Newsletter & Stay Updated